• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunocore Holdings Plc ADR (NQ: IMCR )

    34.64 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Immunocore Holdings Plc ADR

    < Previous 1 2 Next >
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore reports third quarter financial results and provides a business update
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to present at the 2024 Cantor Global Healthcare Conference
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore announces transition of Chief Financial Officer
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore reports second quarter financial results and provides a business update
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to present at the Jefferies Global Healthcare Conference
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore reports first quarter financial results and provides a business update
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore announces upcoming presentation and posters at ASCO 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore presented two posters at CROI 2024
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore Prices Upsized Convertible Senior Notes Offering
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore Announces Proposed Convertible Senior Notes Offering
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore announces upcoming presentation and posters at ESMO 2023
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.